Hydroxychloroquine Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
Condition:   Inhibition of Autophagy Synergizes Anti-tumor Effect Interventions:   Drug: 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib;   Drug: RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial. Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 20, 2023 Category: Research Source Type: clinical trials